Form 4: INSMED CEO Lewis Exercises, Sells Shares Under 10b5-1 Plan

INSMED Inc.'s Chair and CEO, William Lewis, exercised stock options and subsequently sold an equal number of common shares on January 20, 2026, as part of a pre-arranged 10b5-1 trading plan.

Summary

• William Lewis, INSMED Inc.'s Chair and CEO, engaged in transactions involving the company's common stock on January 20, 2026.
• Lewis exercised stock options to acquire a total of 10,699 shares: 6,259 shares at an exercise price of $30.46 and 4,440 shares at an exercise price of $17.16.
• Concurrently, Lewis sold 10,699 shares of common stock in multiple transactions at weighted average prices ranging from $156.80 to $160.70 per share.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on September 4, 2025.
• Following these transactions, Lewis directly beneficially owns 306,891 shares of common stock and indirectly owns 233,924 shares through the Katie Procter Dynasty Trust and 50,500 shares through the William Lewis Family Legacy Trust.
• Lewis also retains derivative securities in the form of stock options for 75,109 shares (exercisable at $30.46) and 53,280 shares (exercisable at $17.16).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While insider selling can sometimes be a negative signal, the execution under a 10b5-1 plan makes it a pre-planned, routine event rather than an immediate reaction to new information. The significant profit realized from option exercises is a positive for the executive.

Positives

• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and transparent approach to insider trading.
• The sale prices for the common stock, ranging from $156.80 to $160.70, are significantly higher than the option exercise prices of $30.46 and $17.16, indicating substantial gains for the executive.

Negatives

• The sale of shares by a high-ranking executive, even if pre-planned, can sometimes be perceived negatively by the market as it reduces their direct equity stake.

Future Outlook

NA

Industry Context

This transaction is a routine insider filing for an executive exercising vested stock options and selling shares, a common practice across various industries for liquidity or tax planning, especially when executed under a 10b5-1 plan to mitigate concerns about trading on material non-public information.

Stakeholder Impact

• Shareholders: The sale of shares by the CEO could be interpreted as a slight reduction in management's direct alignment with shareholder interests, though mitigated by the 10b5-1 plan and continued significant holdings.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned transaction by INSMED's CEO, involving the exercise of stock options and the sale of an equivalent number of shares. Such transactions, executed under a 10b5-1 plan, are generally not considered indicative of a change in the company's fundamental outlook or a signal for future stock performance. The executive continues to hold a substantial number of shares directly and indirectly, along with significant unexercised options. Therefore, this specific filing does not provide new information that would warrant a change in investment recommendation; a 'hold' stance is appropriate pending further company-specific or market-wide developments.

Keywords

INSMED Inc., INSM, William Lewis, Insider Trading, Form 4, Stock Options, 10b5-1 Plan, CEO, Director, Equity Sales, Beneficial Ownership